# Individualized Obesity Pharmacotherapy

> **NCT03374956** · PHASE3 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 193 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Phentermine-Topiramate
- **DRUG:** Liraglutide
- **DRUG:** Naltrexone/bupropion
- **DRUG:** Phentermine

## Key facts

- **NCT ID:** NCT03374956
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2022-05-26
- **Final completion:** 2022-05-26
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2023-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374956, "Individualized Obesity Pharmacotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03374956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*